Adenosine A2A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease

Journal of Immunology

Volumn 190, Issue 1, 2013, Pages 458-468

  Han, Kyu Lee ^a   Thomas, Stephenie V M ^a   Koontz, Sherry M ^a   Changpriroa, Cattlena M ^a   Ha, Seung Kwon ^b   Malech, Harry L ^a   Kang, Elizabeth M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SK Chemicals   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR AGONIST; APADENOSON; ATL 1223; ATL 370; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR AGONIST; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; PURINE DERIVATIVE;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; COLON; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; SKIN; SPLEEN; TARGET ORGAN; TREATMENT DURATION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; DBA MOUSE; DOWN REGULATION; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TRANSPLANTATION; UPREGULATION;

ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLOHEXANECARBOXYLIC ACIDS; DOWN-REGULATION; FEMALE; GRAFT VS HOST DISEASE; IMMUNE TOLERANCE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; PURINES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84871839897     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201325     Document Type: Article

References (52)

1. Reddy, P. 2003. Pathophysiology of acute graft-versus-host disease. Hematol. Oncol. 21: 149-161. (Pubitemid 38146266)
2. + regulatory T cells. Nat. Immunol. 4: 330-336.
3. + T regulatory cells. Nat. Immunol. 4: 337-342.
4. Semple, K., Y. Yu, D. Wang, C. Anasetti, and X. Z. Yu. 2011. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. Biol. Blood Marrow Transplant. 17: 309-318.
5. Feng, G., T. Chan, K. J. Wood, and A. Bushell. 2009. Donor reactive regulatory T cells. Curr. Opin. Organ Transplant. 14: 432-438.
6. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196: 389-399.
7. + regulatory T cells during acute graft-versus-host disease. Blood 106: 3300-3307.
8. + regulatory T cell-mediated suppression of experimental graft-versus-host disease. J. Immunol. 185: 3866-3872.
9. Wolf, D., A. M. Wolf, D. Fong, H. Rumpold, A. Strasak, J. Clausen, and D. Nachbaur. 2007. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 83: 1107-1113. (Pubitemid 46659123)
10. + T cells induces alloantigen-specific tolerance that can prevent GVHD lethality in vivo. Biol. Blood Marrow Transplant. 13: 530-542.
11. 2A agonists in development for the treatment of inflammation. Expert Opin. Investig. Drugs 14: 797-806.
12. 2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290: F828-F837.
13. 2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. 203: 2639-2648.
14. Linden, J. 2005. Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. 67: 1385-1387. (Pubitemid 40594134)
15. 2A adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol. 177: 2765-2769.
16. 2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 129: 26-33.
17. 2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res. Ther. 8: R53.
18. Montesinos, M. C., J. S. Yap, A. Desai, I. Posadas, C. T. McCrary, B. N. Cronstein. 2000. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43: 656-663.
19. 2A) adenosine receptor: an introduction. Br. J. Pharmacol. 153(Suppl 1): S27-S34.
20. 2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation. J. Leukoc. Biol. 87: 345-354.
21. Deaglio, S., K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204: 1257-1265. (Pubitemid 46919862)
22. 2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br. J. Pharmacol. 153(Suppl. 1): S457-S464.
23. 2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111: 251-259.
24. Zakrzewski, J. L., A. A. Kochman, S. X. Lu, T. H. Terwey, T. D. Kim, V. M. Hubbard, S. J. Muriglan, D. Suh, O. M. Smith, J. Grubin, et al. 2006. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat. Med. 12: 1039-1047. (Pubitemid 44353385)
25. Choi, S. W., S. Islam, J. K. Greenson, J. Levine, R. Hutchinson, G. Yanik, D. H. Teitelbaum, J. L. Ferrara, and K. R. Cooke. 2005. The use of laparoscopic liver biopsies in pediatric patients with hepatic dysfunction following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 36: 891-896. (Pubitemid 41655616)
26. Zhou, L., D. Askew, C. Wu, and A. C. Gilliam. 2007. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J. Invest. Dermatol. 127: 281-292. (Pubitemid 46106903)
27. Akpek, G., W. Chinratanalab, L. A. Lee, M. Torbenson, J. P. Hallick, V. Anders, and G. B. Vogelsang. 2003. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol. Blood Marrow Transplant. 9: 46-51. (Pubitemid 41123053)
28. Vokaer, B., N. Van Rompaey, P. H. Lemaître, F. Lhommé, C. Kubjak, F. S. Benghiat, Y. Iwakura, M. Petein, K. A. Field, M. Goldman, et al. 2010. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J. Immunol. 185: 3417-3425.
29. + suppressive T cells in colorectal cancer tissue. Gut 58: 520-529.
30. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108: 390-399.
31. + T cells. J. Immunol. 174: 1073-1080.
32. Koreth, J., and J. H. Antin. 2008. Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol 1: 111.
33. Holler, E. 2002. Cytokines, viruses, and graft-versus-host disease. Curr. Opin. Hematol. 9: 479-484. (Pubitemid 35191115)
34. Kim, S. S. 2007. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. Ann. Pharmacother. 41: 1436-1444. (Pubitemid 47311363)
35. 2A receptor agonists as anti-inflammatory agents. Curr. Opin. Investig. Drugs 4: 1313-1319.
36. Butler, J. J., J. S. Mader, C. L. Watson, H. Zhang, J. Blay, and D. W. Hoskin. 2003. Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways. J. Cell. Biochem. 89: 975-991. (Pubitemid 36927729)
37. + T cells. Bone Marrow Transplant. 39: 537-545.
38. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9: 1144-1150.
39. + immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196: 401-406.
40. Gaidot, A., D. A. Landau, G. H. Martin, O. Bonduelle, Y. Grinberg-Bleyer, D. Matheoud, S. Grégoire, C. Baillou, B. Combadière, E. Piaggio, and J. L. Cohen. 2011. Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. Blood 117: 2975-2983.
41. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493-3499.
42. Komanduri, K. V., and R. E. Champlin. 2011. Can Treg therapy prevent GVHD? Blood 117: 751-752.
43. Brunstein, C. G., J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. Levine, C. H. June, P. Rubinstein, et al. 2011. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117: 1061-1070.
44. Tsukamoto, H., P. Chernogorova, K. Ayata, U. V. Gerlach, A. Rughani, J. W. Ritchey, J. Ganesan, M. Follo, R. Zeiser, L. F. Thompson, and M. Idzko. 2012. Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease. Blood 119: 4554-4564.
45. Sauer, A. V., I. Brigida, N. Carriglio, R. J. Hernandez, S. Scaramuzza, D. Clavenna, F. Sanvito, P. L. Poliani, N. Gagliani, F. Carlucci, et al. 2012. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood 119: 1428-1439.
46. Morabito, L., M. C. Montesinos, D. M. Schreibman, L. Balter, L. F. Thompson, R. Resta, G. Carlin, M. A. Huie, and B. N. Cronstein. 1998. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101: 295-300. (Pubitemid 28067325)
47. Cronstein, B. N., D. Naime, and G. Firestein. 1995. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum. 38: 1040-1045.
48. Blackburn, M. R., C. O. Vance, E. Morschl, and C. N. Wilson. 2009. Adenosine receptors and inflammation. Handb Exp Pharmacol 193: 215-269.
49. Chen, B. J., R. E. Morris, and N. J. Chao. 2000. Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol. Blood Marrow Transplant. 6 (5A): 529-536.
50. Palmer, J. M., B. J. Chen, D. DeOliveira, N. D. Le, and N. J. Chao. 2010. Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells. Bone Marrow Transplant. 45: 379-384.
51. + regulatory T cells: does in vitro evidence translate to the clinical setting? Transplantation 85: 783-789.
52. Sauer, S., L. Bruno, A. Hertweck, D. Finlay, M. Leleu, M. Spivakov, Z. A. Knight, B. S. Cobb, D. Cantrell, E. O'Connor, et al. 2008. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 105: 7797-7802. (Pubitemid 351872718)